An Open-Label Evaluation of LAMICTAL (Lamotrigine) Monotherapy for the Treatment of Newly-Diagnosed Typical Absence Seizures in Children and Adolescents.

Trial Profile

An Open-Label Evaluation of LAMICTAL (Lamotrigine) Monotherapy for the Treatment of Newly-Diagnosed Typical Absence Seizures in Children and Adolescents.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Lamotrigine (Primary)
  • Indications Absence epilepsy
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from Dec 2004 to Nov 2004 as reported by Clinicaltrials.gov.
    • 14 Oct 2008 Trial phase changed from III to I as reported by ClinicalTrials.gov.
    • 29 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top